Compare Biogen Inc (BIIB) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Biogen Inc trades at $207.91 (market cap $30.13B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52. The key difference: Biogen Inc is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | SGOV | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Fixed Income |
52-Week High | $216.63 | $100.74 |
52-Week Low | $128.93 | $100.28 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.515 with minimal daily movement (+0.01%). The ETF shows bearish technical signals with moving averages indicating selling pressure, though oscillators are neutral. Recent institutional activity shows mixed positioning with some firms increasing stakes while others reduced exposure. The fund provides exposure to ultra-short-term Treasury bonds with monthly distributions, currently yielding approximately 3.8%.
SGOV serves as a defensive cash alternative amid market volatility, offering principal protection and minimal interest rate risk. The fund benefits from rising benchmark rates but faces pressure from potential Fed rate hikes and inflation concerns. Current macro uncertainty and steepened yield curve create both opportunity and risk for Treasury-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
